for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Codexis, Inc.

CDXS.C

Latest Trade

11.80USD

Change

0.00(0.00%)

Volume

414

Today's Range

11.45

 - 

11.80

52 Week Range

8.59

 - 

18.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.80
Open
11.45
Volume
414
3M AVG Volume
8.92
Today's High
11.80
Today's Low
11.45
52 Week High
18.85
52 Week Low
8.59
Shares Out (MIL)
59.02
Market Cap (MIL)
691.70
Forward P/E
-26.94
Dividend (Yield %)
--

Next Event

Q2 2020 Codexis Inc Earnings Release

Latest Developments

More

Codexis And Molecular Assemblies Partner To Transform The Field Of DNA Synthesis

Codexis Inc - Under Takeda Agreement, Takeda Will Make A One Time, Non-Refundable Cash Payment To Company Of $8.5 Mln

Codexis Reports Q4 Non-GAAP Earnings Per Share $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Codexis, Inc.

Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Industry

Biotechnology & Drugs

Contact Info

200 Penobscot Dr

REDWOOD CITY, CA

94063-4718

United States

+1.650.4218100

https://www.codexis.com/

Executive Leadership

Bernard J. Kelley

Independent Chairman of the Board

John J. Nicols

President, Chief Executive Officer, Director

Ross Taylor

Chief Financial Officer, Senior Vice President

Thomas R. Baruch

Independent Director

Pam P. Cheng

Independent Director

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.500

2018

-0.210

2019

-0.210

2020(E)

-0.435
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.24
Price To Book (MRQ)
6.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.01
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-13.79
Return on Equity (TTM)
-11.53

Latest News

Latest News

BRIEF-Codexis And Molecular Assemblies Partner To Transform The Field Of DNA Synthesis

* CODEXIS AND MOLECULAR ASSEMBLIES PARTNER TO TRANSFORM THE FIELD OF DNA SYNTHESIS

BRIEF-Codexis, Alphazyme Partner To Offer Novel Enzymes To Life Science And Diagnostic Markets

* CODEXIS AND ALPHAZYME PARTNER TO OFFER NOVEL ENZYMES TO LIFE SCIENCE AND DIAGNOSTIC MARKETS

BRIEF-Codexis Inc - Under Takeda Agreement, Takeda Will Make A One Time, Non-Refundable Cash Payment To Company Of $8.5 Mln

* CODEXIS INC - UNDER TAKEDA AGREEMENT, TAKEDA WILL MAKE A ONE TIME, NON-REFUNDABLE CASH PAYMENT TO COMPANY OF $8.5 MILLION

BRIEF-Codexis Reports Q4 Non-GAAP Earnings Per Share $0.02

* CODEXIS REPORTS 2019 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Codexis And Nestlé Health Science Sign Development Deal

* CODEXIS AND NESTLÉ HEALTH SCIENCE SIGN DEVELOPMENT AGREEMENT TO ADVANCE THERAPEUTIC CANDIDATE TOWARDS CLINICAL STUDIES AND EXTEND STRATEGIC COLLABORATION AGREEMENT

BRIEF-Codexis Reports Q1 Loss Per Share $0.10

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Porton Fine Chemicals signs strategic agreement with Codexis on enzymatic related business

* Says it signed strategic agreement with U.S. company Codexis Inc on enzymatic related business

BRIEF-Codexis Announces Proposed Public Offering Of Common Stock

* CODEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Codexis Q4 Non-Gaap Earnings Per Share $0.06

* CODEXIS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Telemark Asset Management LLC reports 6.72 pct passive stake in Codexis as of Nov 10

* Telemark Asset Management LLC reports 6.72 percent passive stake in Codexis Inc as of November 10 - SEC Filing Source text: [http://bit.ly/2AYhX8Y] Further company coverage:

BRIEF-Codexis Q3 non-gaap loss per share $0.17

* Codexis reports financial results for the third quarter of 2017

BRIEF-Codexis Inc, Nestlé Health Science enter strategic collaboration​

* Codexis Inc - co, Nestlé Health Science enter strategic collaboration

BRIEF-Codexis Q2 loss per share $0.13

* Codexis reports financial results for the second quarter of 2017

BRIEF-Codexis ‍wins summary judgment of patent infringement against EnzymeWorks​

* Codexis Inc - obtains court order awarding summary judgment of patent infringement against EnzymeWorks

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up